All In Biotech

Drug Trial Radar · NCT06682000

Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension

A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of DWC202404 and DWC202314 Combination Therapy in Patients With Essential Hypertension Inadequately Controlled on DWC202404 Monotherapy

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

192

Actual

Start

Jan 20, 2025

Primary completion

Oct 2, 2025

Study completion Oct 2, 2025

Sponsor

Sponsor type
Industry
First posted
Nov 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of DWC202404 and DWC202314 Combination Therapy in Patients with Essential Hypertension Inadequately Controlled on DWC202404 Monotherapy

Conditions

  • Hypertension
  • Essential Hypertension

Interventions

  • DWC202404, DWC202314Drug

    \- 2 tablet, Oral, Once a day

  • DWC202404, DWC202314PDrug

    \- 2 tablet, Oral, Once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of MSSBP (Mean Sitting Systolic Blood Pressure) based on baselineTime frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hanyang University Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.